Data updated: Jun 28, 2026
Bacterial Infections Clinical Trial Landscape
Bacterial Infections is being studied across 172 clinical trials registered since 2008, with 26 programs currently active. The competitive pipeline includes 5 active Phase 3 trials, 7 active Phase 2 trials, and 4 active Phase 1 trials.
Top industry sponsors include Pfizer, Qpex Biopharma, Inc., CanSino Biologics Inc..
Trial activity
26 active / 172 total since 2008
Active by phase 5 Ph3 / 35 7 Ph2 / 32 4 Ph1 / 73 10 Ph4 / 32
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Pfizer 2 7 2
Qpex Biopharma, Inc. 1 8 0
CanSino Biologics Inc. 1 2 0
Grifols Therapeutics LLC 1 0 0
Bausch Health Americas, Inc. 1 0 0
Vasomune Therapeutics, Inc. 1 0 0
Joincare Pharmaceutical Group Industry Co., Ltd 1 0 0
Saptalis Pharmaceuticals LLC 1 0 0
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC) 1 0 0
Merck 0 7 0
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) 0 5 0
Melinta Therapeutics, Inc. 0 5 0
Evopoint Biosciences Inc. 0 4 0
Tetraphase Pharmaceuticals, Inc 0 4 0
MCM Vaccines B.V. 0 4 0
How the field has grown
New-trial starts peaked in 2021 (14 registered); 2025 saw 7. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (15 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 9
2017 8
2018 7
2019 7
2020 9
2021 14
2022 6
2023 12
2024 9
2025 7
2026 6
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (2) 408
2017 (1) 199
2018 (0) 0
2019 (2) 1,113
2020 (2) 169
2021 (3) 128
2022 (1) 386
2023 (0) 0
2024 (1) 28
2025 (2) 469
2026 (1) 70
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT06592586 ACTIVE NOT RECRUITING
A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women
Minervax ApS n=338
NCT05645107 RECRUITING
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics LLC n=386
NCT07503600 NOT YET RECRUITING
The Effect of Adjunctive Melatonin With Colistin in Patients With Multidrug-Resistant Gram-Negative Bacterial Infections
Ain Shams University n=70
NCT07017777 RECRUITING
A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)
CanSino Biologics Inc. n=600
NCT06444802 NOT YET RECRUITING
Model-informed Precision Dosing for Linezolid
University of Hamburg-Eppendorf n=28
NCT03969901 COMPLETED
Safety, Tolerability, Efficacy and Pharmacokinetics of Imipenem/Cilastatin/Relebactam (MK-7655A) in Pediatric Participants With Gram-negative Bacterial Infection (MK-7655A-021)
Merck Sharp & Dohme LLC n=115
NCT03925480 COMPLETED
Preventing Young Infant Infections Using Azithromycin in Labour (PreYIAL) Trial
Murdoch Childrens Research Institute n=2,110
NCT03896685 COMPLETED
Evaluating Newly Approved Drugs in Combination Regimens for Multidrug-Resistant TB With Fluoroquinolone Resistance (endTB-Q)
Médecins Sans Frontières, France n=323
NCT02814916 COMPLETED
Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA
AbbVie n=199
NCT04841369 COMPLETED
Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)
CanSino Biologics Inc. n=3,420
NCT03580044 TERMINATED
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria
Pfizer n=15
NCT04847921 TERMINATED
Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
University of Colorado, Denver n=11
NCT05689229 COMPLETED
Aerosolized Versus Intravenous Colistin-based Antimicrobial Regimens in Hospitalized COVID-19 Patients With Bacterial Coinfection: A Randomized Controlled Trial
Beni-Suef University n=128
NCT01817075 COMPLETED
Chlorhexidine Gluconate Cleansing in Preventing Central Line Associated Bloodstream Infection and Acquisition of Multi-drug Resistant Organisms in Younger Patients With Cancer or Undergoing Donor Stem Cell Transplant
Children's Oncology Group n=177
NCT01371656 COMPLETED
Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Children's Oncology Group n=624
NCT01341639 COMPLETED
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)
MCM Vaccines B.V. n=1,250
NCT01480258 COMPLETED
Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)
MCM Vaccines B.V. n=1,315
NCT01553279 COMPLETED
Immunogenicity and Safety of V419 (PR51) in Combination With MCC in Infants and Toddlers (V419-011)
MCM Vaccines B.V. n=284
NCT02378480 COMPLETED
Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
Paratek Pharmaceuticals Inc n=655
NCT02753387 COMPLETED
Effect of Oral Preparation on Bacterial Colonization of the Pharyngeal Mucosa in Surgery of Head and Neck Cancer
Rennes University Hospital n=80
NCT02877927 COMPLETED
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
Paratek Pharmaceuticals Inc n=735
NCT01337167 COMPLETED
Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)
Merck Sharp & Dohme LLC n=1,473
NCT01340937 COMPLETED
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
Merck Sharp & Dohme LLC n=2,808
NCT02452047 COMPLETED
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
Merck Sharp & Dohme LLC n=50
NCT01421511 COMPLETED
TR-701 FA vs Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=666
NCT01170221 COMPLETED
TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) n=667
NCT03124199 COMPLETED
Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection
Fundación de Investigación Biomédica - Hospital Universitario de La Princesa n=40
NCT01984684 COMPLETED
Delafloxacin vs Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Melinta Therapeutics, Inc. n=850
NCT01811732 COMPLETED
Delafloxacin Versus Vancomycin and Aztreonam for the Treatment of Acute Bacterial Skin and Skin Structure Infections
Melinta Therapeutics, Inc. n=660
NCT01839175 COMPLETED
Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination
Sanofi Pasteur, a Sanofi Company n=350
NCT02066402 COMPLETED
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Bayer n=598
NCT02361866 COMPLETED
To Evaluate the Effectiveness(Immunogeneicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Adults
Green Cross Corporation n=376
NCT01402713 COMPLETED
To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children
Green Cross Corporation n=311
NCT01608815 COMPLETED
Study of a Single Dose of SP093 Typhoid Vi Polysaccharide Vaccine in Japanese Subjects
Sanofi Pasteur, a Sanofi Company n=200
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only